Hyperkalemia in chronic heart failure with renal dysfunction or diabetes mellitus: Results from the TREAT HF study.

Murat S., Kaya H., Çavuşoğlu Y., Yılmaz M. B.

Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, cilt.49, ss.198-205, 2021 (ESCI) identifier identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 49
  • Basım Tarihi: 2021
  • Doi Numarası: 10.5543/tkda.2021.58675
  • Dergi Adı: Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Central & Eastern European Academic Source (CEEAS), EMBASE, MEDLINE, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.198-205
  • Anahtar Kelimeler: Hyperkalemia, heart failure, diabetes mellitus, chronic kidney disease, CONVERTING-ENZYME-INHIBITORS, VENTRICULAR SYSTOLIC FUNCTION, SERUM POTASSIUM, PREDICTORS, RISK, ASSOCIATION, CANDESARTAN, ALISKIREN, OUTCOMES
  • Eskişehir Osmangazi Üniversitesi Adresli: Evet

Özet

Objective: Chronic kidney disease (CKD) and diabetes mellitus (DM) are common comorbidities in heart failure (HF). Patients with HF are at a high risk of hyperkalemia, and are therefore undertreated with respect to disease-modifying therapies. The Turkish Research Team-Heart Failure (TREAT HF) data were analyzed for the evaluation of hyperkalemia in real-life clinical practice in HF patients with CKD or DM.